This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.
本发明涉及用于改进癌症诊断和治疗方法的新型放射性药物共轭物。放射性药物共轭物依次包括:一种靶向肿瘤细胞的代谢物,与一种能够包含放射性核素的
螯合剂结合,与一种能够在体外或体内与 EPR 制剂结合的连接体结合;或一种能够包含放射性核素的
螯合剂,与一种靶向肿瘤细胞的代谢物结合,与一种能够在体外或体内与 EPR 制剂结合的连接体结合。本发明的放射性药物共轭物提供了主动和被动的靶向放射性核素递送系统,有助于改善用于诊断和治疗癌症的放射性药物的
生物分布和药理毒性。